On Thursday, Juniper Networks, Inc. (NYSE:JNPR)’s shares inclined 0.87% to $27.92.
Juniper Networks, Inc. (JNPR) declared that it has captured top honors in two ‘Best of Show’ award categories at Interop Tokyo 2015, underscoring the company’s commitment to delivering innovative networking technology for enterprise and service provider customers.
One of Asia’s largest network computing trade shows, Interop Tokyo recognizes the most innovative products, solutions and services among hundreds of nominated submissions. Juniper Networks has been an annual award recipient at Interop Tokyo since 2007.
This year, the event is predictable to attract more than 140,000 attendees and features keynote addresses, a conference program and an expo area for vendor showcases.
Acknowledging innovative products and data center architecture which have moved business technology forward, the Best of Show awards were presented to Juniper Networks by a judging panel of IT industry experts who carried out a rigorous examination of products and solutions exhibited by more than 300 companies at Interop Tokyo 2015.
Juniper Networks, Inc. designs, develops, and sells high-performance network products and services worldwide. It provides various routing products, counting ACX series universal access routers to deploy new high-bandwidth services; MX series Ethernet routers that functions as a universal edge platform; M series edge routers; PTX series packet transport routers; and T series routers.
Synta Pharmaceuticals Corp. (NASDAQ:SNTA)’s shares gained 1.24% to $2.45.
Synta Pharmaceuticals Corp. (SNTA) declared updates to its clinical program for Ganetespib, a next-generation inhibitor of the chaperone protein Hsp90. Ganetespib is presently being studied in several large, randomized studies, counting the Phase 3 GALAXY-2 trial in non-small cell lung cancer, in addition to a number of other investigator-sponsored studies in various malignancies, counting acute myeloid leukemia, breast cancer and ovarian cancer.
The Company declared recently that the first patient has been enrolled in the Phase 2 portion of the GANNET53 study, a randomized, pan-European study evaluating the combination of ganetespib and paclitaxel vs. paclitaxel alone in over 200 patients with metastatic, predominantly p53 mutant, platinum-resistant ovarian cancer. Enrollment in the Phase 2 portion follows the successful completion of Phase 1, the results of which were recently presented at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago. The Phase 1 data demonstrated that the combination of ganetespib 150 mg/m² with paclitaxel 80 mg/m² once weekly for 3 out of 4 weeks was generally well tolerated, with no dose limiting toxicities, and was therefore chosen for the randomized phase 2 trial. GANNET53 is sponsored by Innsbruck Medical University in Austria and funded by the European Commission.
Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on the research, development, and commercialization of novel oncology medicines for cancer patients. Its lead oncology drug candidate comprises ganetespib, an Hsp90 inhibitor, which is in Phase III clinical trial for the treatment of non-small cell lung cancer; in Phase II clinical trial for patients with hormone receptor positive metastatic breast cancer; in Phase I clinical trial for the treatment of HER2 positive patients with metastatic breast cancer; in Phase II/III clinical trial for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome; in Phase I/II trial of paclitaxel in combination with ganetespib in patients with platinum-resistant ovarian cancer; and in Phase I/II trial in combination with the mTOR inhibitor sirolimus in patients with refractory sarcoma.
At the end of Thursday’s trade, Home Depot Inc (NYSE:HD)‘s shares surged 0.29% to $111.29.
Home Depot Inc (HD) accomplished a public offering of $1,250,000,000 aggregate principal amount of its 2.625% Senior Notes due 2022 and $1,250,000,000 aggregate principal amount of its 4.250% Senior Notes due 2046 (collectively, the “Notes”). The offering of the Notes was made following the Company’s shelf registration statement on Form S-3 (Registration No. 333-183621) filed with the Securities and Exchange Commission (the “SEC”) on August 29, 2012, counting a related prospectus and prospectus supplement filed with the SEC on August 29, 2012 and May 29, 2015, respectively.
In connection with the offering of the Notes, the Company reached an Underwriting Agreement dated May 28, 2015 (the “Underwriting Agreement”) among the Company and Credit Suisse Securities (USA) LLC, Goldman, Sachs & Co., J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, as representatives of the underwriters named therein (together, the “Underwriters”). Following the Underwriting Agreement, the Company agreed to sell the Notes to the Underwriters, and the Underwriters agreed to purchase the Notes for resale to the public. The Underwriting Agreement comprises customary representations, warranties and covenants by the Company. It also provides for customary indemnification by each of the Company and the Underwriters against certain liabilities and customary contribution provisions in respect of those liabilities.
The Home Depot, Inc. operates as a home improvement retailer. It operates The Home Depot stores that sell various building materials, home improvement products, and lawn and garden products, in addition to provide installation, home maintenance, and professional service programs to do-it-yourself, do-it-for-me, and professional customers.
Nuance Communications Inc. (NASDAQ:NUAN), ended its Thursday’s trading session with 1.59% gain, and closed at $18.17.
Nuance Communications Inc. (NUAN) is a software technology corporation that provides businesses and customers across the world with voice and language solutions.
TheStreet’s Bryan Ashenberg and Bob Lang of Trifecta Stocks have identified Nuance Communications as the “Chart of the Day.” Here is what Ashenberg and Lang had to say about it:
Nuance Communications’ chart shows a stair-step pattern of higher highs and higher lows. This shows the classic cup-handle patterns that have been the best chart patterns throughout history.
This stock is showing some amazing qualities here as the uptrend started in late April. Strong turnover and very solid technical signals have Nuance poised for more upside.
Nuance Communications, Inc. provides voice and language solutions for businesses and consumers worldwide. It offers hosted and on-premise solutions and services that provide platforms to generate and distribute clinical documentation through the use of dictation and transcription features; clinical documentation improvement programs; and speech recognition solutions for radiology, cardiology, pathology, and related specialties enabling healthcare providers to dictate, edit, and sign reports without manual transcription.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.